Related Experiment Video
Updated: May 20, 2026
Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
Published on: February 14, 2011
Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies
Dirk Mentzer1, Jürgen Prestel, Ortwin Adams
1Department of Safety of Medicinal Products and Medical Devices, Paul-Ehrlich-Institute, Federal Institute for Vaccines and Biomedicines, Langen, Germany. dirk.mentzer@pei.de
Background:
Novel immunosuppressive/modulating therapies with monoclonal antibodies (MABs) have been associated with progressive multifocal leukoencephalopathy (PML), a potentially fatal disease of the brain caused by the JC virus. Taking the complex diagnostic testing and heterogeneous clinical presentation of PML into account, an agreed case definition for PML is a prerequisite for a thorough assessment of PML.
Objective/Methods:
A working group was established to develop a standardised case definition for PML which permits data comparability across clinical trials, postauthorisation safety studies and passive postmarketing surveillance. The case definition is designed to define levels of diagnostic certainty of reported PML cases following treatment with MABs. It was subsequently used to categorise retrospectively suspected PML cases from Germany reported to the Paul-Ehrlich-Institute as the responsible national competent authority.
Results:
The algorithm of the case definition is based on clinical symptoms, PCR for JC virus DNA in cerebrospinal fluid, brain MRI, and brain biopsy/autopsy. The case definition was applied to 119 suspected cases of PML following treatment with MABs and is considered to be helpful for case ascertainment of suspected PML cases for various MABs covering a broad spectrum of indications. Even if the available information is not yet complete, the case definition provides a level of diagnostic certainty.
Conclusions:
The proposed case definition permits data comparability among different medicinal products and among active as well as passive surveillance settings. It may form a basis for meaningful risk analysis and communication for regulators and healthcare professionals.
Insights
A new case definition for progressive multifocal leukoencephalopathy (PML) aids in standardizing diagnosis for patients treated with monoclonal antibodies (MABs). This definition improves data comparability and risk assessment for this rare but serious JC virus brain infection.
Area of Science:
- Neurology
- Infectious Diseases
- Immunology
Background:
- Monoclonal antibodies (MABs) are linked to progressive multifocal leukoencephalopathy (PML), a severe JC virus brain infection.
- PML diagnosis is challenging due to complex testing and varied clinical signs.
Purpose of the Study:
- To establish a standardized case definition for PML following MAB treatment.
- To enable data comparability across studies and surveillance for MAB-associated PML.
- To define diagnostic certainty levels for reported PML cases.
Main Methods:
- A working group developed a standardized PML case definition.
- The definition incorporates clinical symptoms, JC virus PCR, MRI, and biopsy/autopsy findings.
- Applied retrospectively to 119 suspected PML cases in Germany.
Main Results:
- The case definition provides a structured algorithm for PML diagnosis.
- It was successfully applied to suspected PML cases associated with various MABs.
- The definition offers a level of diagnostic certainty even with incomplete data.
Conclusions:
- The proposed PML case definition enhances data comparability across MABs and surveillance settings.
- It supports meaningful risk analysis and communication for regulators and healthcare professionals.
- Facilitates consistent assessment of PML risk with MAB therapies.